Table 3.
Costs, LYs, and incremental cost-effectiveness of strategies.
| Undiscounted Cost (USD) | Undiscounted LYs | ||
| Status quo | 1,938,996 | 7203 | |
| Improved switching | 2,025,987 | 7358 | |
| PDR testing | 2,203,694 | 7318 | |
| DTG | 1,838,619 | 7378 | |
| DTG + improved switching | 1,868,298 | 7430 | |
| Discounted Cost (USD) | Discounted LYs | ICER (USD/LY gained) | |
| Status quo | 1,697,253 | 6301 | N/A |
| Improved switching | 1,772,844 | 6432 | 579 a |
| PDR testing | 1,944,011 | 6399 | N/A |
| DTG | 1,610,327 | 6448 | N/A |
| DTG + improved switching | 1,636,073 | 6491 | 591 b |
Costs and LYs are per 1000 children initiating ART at 3 years of age, over a 10-year time horizon. Costs are reported in 2020 USD. Discounted costs and LYs were discounted 3% annually. N/A = not applicable; LYs = life years; ICER = incremental cost-effectiveness ratio. a ICER was calculated by considering only strategies without DTG availability. No ICER was calculated for PDR testing because it was dominated by improved switching (PDR testing gained fewer LYs at a greater cost compared to improved switching). b ICER was calculated by considering only strategies with DTG availability.